Therapy Areas: Allergy
LFB Receives FDA Approval of Sevenfact, a New Recombinant Coagulation Factor VIIa, for the Treatment of Adults and Adolescents with Hemophilia A or B with Inhibitors
8 April 2020 - - The US Food and Drug Administration has approved the Biologics License Application 2061 for Sevenfact, a new recombinant coagulation Factor VIIa [coagulation factor VIIa (recombinant)...
Ridgeback LP wins FDA clearance to commence human testing of EIDD-2801 for potential treatment for COVID-19
7 April 2020 - Biotechnology company Ridgeback Biotherapeutics LP said on Monday that it has received US Food and Drug Administration (FDA) approval to initiate human clinical testing of investigation...
Evolve BioSystems Inc partners with Janssen to study B. infantis EVC001 in reduction of childhood atopic dermatitis
27 March 2020 - Human health company Evolve BioSystems Inc said on Thursday that it plans to conduct a clinical study in children at risk for developing atopic dermatitis in partnership with Janssen R...
Mesa Biotech granted FDA Emergency Use Authorization for 30 minute POC molecular COVID-19 Test
25 March 2020 - Molecular diagnostic test provider Mesa Biotech announced on Tuesday the receipt of US Food & Drug Administration (FDA) Emergency Use Authorization (EUA) for its Accula SARS-CoV-2 ...
Mesa Biotech announces funding from BARDA for development of 30-minute SARS-CoV-2 test
20 March 2020 - Molecular diagnostic company Mesa Biotech Inc reported on Thursday the receipt of a USD561,000 contract from the US Department of Health and Human Services (HHS) Biomedical Advanced Re...
AbCellera partners with Lilly to co-develop antibody therapies for treatment of COVID-19
13 March 2020 - Healthcare companies AbCellera and Eli Lilly and Company (NYSE:LLY) reported on Thursday the signing of an agreement to co-develop antibody products for the treatment and prevention of...